Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Growth Potential of the Lupus Nephritis Market Size Over 2025-2034?
The lupus nephritis market size has grown strongly in recent years. It will grow from $1.94 billion in 2024 to $2.08 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing research investments in lupus nephritis, rising incidence of autoimmune diseases, rising healthcare expenditure, growing adoption of biologics, and growing popularity of telemedicine.
The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to " $2.78 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to the rise in physician awareness, increasing adoption of biologic therapies, increasing number of specialty clinics, increasing importance of renal transplantation, and increasing access to nephrology services. Major trends in the forecast period include advancements in biologic therapies, personalized medicine approaches, novel diagnostic biomarkers, expansion of clinical trials, and advancements in stem cell therapy.
Get your free report sample today:
What Are the Leading Drivers Behind the Growth of the Lupus Nephritis Market?
The increasing prevalence of genetic predisposition is expected to propel the growth of the lupus nephritis market going forward. Genetic predisposition refers to an individual's inherited genetic traits that increase their likelihood of developing certain diseases or conditions. The increasing prevalence of genetic predisposition is due to factors such as inheritance, environmental influences, and mutations in specific genes. The increasing prevalence of genetic predisposition plays a significant role in the development of lupus nephritis, emphasizing the impact of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the UK CF Registry recorded 11,148 registered patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% increase in individuals with cystic fibrosis (CF). Therefore, the increasing prevalence of genetic predisposition is driving the growth of the lupus nephritis market.
Which Market Segment Offers the Most Significant Growth Opportunities in the Lupus Nephritis Market?
The lupus nephritismarket covered in this report is segmented –
1) By Stage: Class 1; Class 2; Class 3; Other Stages
2) By Drug Class: Immunosuppressive Drugs; Corticosteroids; Biological Agents; Antimalarial Drugs
3) Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Class 1: Asymptomatic Cases; Mild Proteinuria; Incidental Diagnosis.
2) By Class 2: Mild Hematuria; Low-Grade Proteinuria; Minimal Immune Complex Deposition.
3) By Class 3: Active Lesions; Chronic Sclerotic Lesions; Crescent Formation.
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis); Class 5 (Membranous Lupus Nephritis); Class 6 (Advanced Sclerotic Lupus Nephritis)
Which Disruptive Trends Are Reshaping the Competitive Landscape of the Lupus Nephritis Market?
Major companies operating in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to enhance treatment efficacy and improve long-term kidney outcomes for patients. Second-generation calcineurin inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on data from the AURORA Clinical Program, which demonstrated its safety and efficacy. The approval marks a significant milestone in expanding treatment options for lupus nephritis patients in Japan, improving disease management and outcomes.
Who Are the Top Industry Players Driving the Lupus Nephritis Market Growth?
Major companies operating in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, Bionxt Solutions.
Get the detailed lupus nephritis market report today
Which Regional Markets Offer the Most Promising Growth Opportunities for the Lupus Nephritis Market?
Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in the lupus nephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment